BabafemiOlapojuTaiwoMD

Gene Stollerman Professor in Medicine-Infectious Diseases Chief, Infectious Diseases Division Northwestern University Medical School

Join to view full profile

Dr. Taiwo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Taiwo's full profile

Already have an account?

Office
676 N Saint Clair St
Chicago, IL 60611
Phone+1 312-926-8358

Fax+1 312-926-9630

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Infectious Disease, 2005 - 2007
Berkshire Medical CenterResidency, Internal Medicine, 1993 - 1997
University of IbadanClass of 1990

Certifications & Licensure

IL State Medical License 2005 - 2026
NC State Medical License 1996 - 2006

Clinical Trials

Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1 Start of enrollment: 2010 May 01
Completed
Phase 2
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir Start of enrollment: 2013 Apr 25
Completed
Phase 4
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection Start of enrollment: 2014 May 30
Completed
Phase 1
Modulation of Immune Activation by Aspirin Start of enrollment: 2014 Aug 01
Completed
Phase 2
Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure Start of enrollment: 2014 Dec 01
Completed
Phase 3
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART) Start of enrollment: 2015 Dec 21
Completed
Phase 1, Phase 2
PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332) Start of enrollment: 2017 Mar 14
COMPLETED
PHASE3
Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 Start of enrollment: 2019 Dec 31
COMPLETED
PHASE2
A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV Start of enrollment: 2023 May 30
COMPLETED
PHASE2
Roles: Contact
Combination Intervention to Enhance Treatment Engagement and Viral Suppression Among Sexual and Gender Minority Youth in Nigeria Start of enrollment: 2024 Nov 28
RECRUITING
NA
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Risk Factors for Viral Non-suppression Among Youth Living with HIV in Nigeria: Findings from the iCARE Nigeria Study.
Mobolanle Balogun, Lisa M Kuhns, Alani S Akanmu, Robert Garofalo, Titilope Badru
AIDS and Behavior. 2025-03-01
Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti-HIV-1 Antibodies.
Marie Høst Pahus, Yu Zheng, Maxine Olefsky, Jesper Damsgaard Gunst, Pablo Tebas
The Journal of Infectious Diseases. 2025-02-20
A Stepped-Wedge, Cluster-Randomized, Multisite Study of Text Messaging Plus Peer Navigation to Improve Adherence and Viral Suppression Among Youth on Antiretroviral Th...
Babafemi O Taiwo, Lisa M Kuhns, Oche Agbaji, Agatha David, Sulaimon Akanmu
Journal of Acquired Immune Deficiency Syndromes. 2025-02-01

Press Mentions

Cultivating Africa’s Research EnterpriseOctober 28th, 2021
Novel Polyclonal Antibody Therapy Meets the Criteria for Graduation to Phase 3 in ACTIV-2 TrialSeptember 28th, 2021
Northwestern Seeking 5,000 Volunteers for COVID-19 Prevention TrialsJuly 28th, 2020
Join now to see all